JNJ

172.25

-0.87%↓

ABBV

197.81

+0.43%↑

AZN

74.88

+1.44%↑

NVS

119.07

+1.22%↑

ABT

130.51

-0.63%↓

JNJ

172.25

-0.87%↓

ABBV

197.81

+0.43%↑

AZN

74.88

+1.44%↑

NVS

119.07

+1.22%↑

ABT

130.51

-0.63%↓

JNJ

172.25

-0.87%↓

ABBV

197.81

+0.43%↑

AZN

74.88

+1.44%↑

NVS

119.07

+1.22%↑

ABT

130.51

-0.63%↓

JNJ

172.25

-0.87%↓

ABBV

197.81

+0.43%↑

AZN

74.88

+1.44%↑

NVS

119.07

+1.22%↑

ABT

130.51

-0.63%↓

JNJ

172.25

-0.87%↓

ABBV

197.81

+0.43%↑

AZN

74.88

+1.44%↑

NVS

119.07

+1.22%↑

ABT

130.51

-0.63%↓

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Avatud

SektorTervishoid

6.8 0.44

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

6.42

Max

7.56

Põhinäitajad
By Trading Economics
Sissetulek	-354K -23M
Müük	-2M 15M
Kasumimarginaal	-151.708
Töötajad	131
EBITDA	-1.2M -21M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+126.09% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	15. aug 2025

Turustatistika
By TradingEconomics
Turukapital	33M 152M
Eelmine avamishind	6.36
Eelmine sulgemishind	6.8

Uudiste sentiment

By Acuity

50%

162 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

5.04 / 5.44 Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2025, 17:49 UTC

Suurimad hinnamuutused turgudel

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11. aug 2025, 17:18 UTC

Suurimad hinnamuutused turgudel

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11. aug 2025, 16:25 UTC

Tulu

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11. aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11. aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11. aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11. aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11. aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11. aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings 2Q Rev $577.9M >BKKT

11. aug 2025, 20:37 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11. aug 2025, 20:22 UTC

Tulu

Exodus Movement 2Q Rev $25.8M >EXOD

11. aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11. aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11. aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11. aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11. aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11. aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11. aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11. aug 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11. aug 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

BBVA Says Sabadell Offer Remains in Effect

11. aug 2025, 16:26 UTC

Omandamised, ülevõtmised, äriostud

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Announced TSB Sale on July 1

11. aug 2025, 16:25 UTC

Omandamised, ülevõtmised, äriostud

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

126.09% tõus

12 kuu keskmine prognoos

Keskmine 15.6 USD 126.09%

Kõrge 24 USD

Madal 7 USD

Põhineb 5 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.04 / 5.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

162 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.